Extended-Release Implants: Re-Vana Therapeutics’ Quest for an Anti-VEGF Grail
During the 38th Congress of the ESCRS, PIE magazine CEO Matt Young had a chance to speak with Michael O’Rourke, CEO of Re-Vana Therapeutics and a 25-year veteran in the ophthalmic industry. Together, they traced Mr. O’Rourke’s winding route to Re-Vana and explored his motivations that led him to the company and its major modus operandi.
…
Patients Failing to Maintain anti-VEGF Injections
I’m going to go out on a limb here and postulate something, namely, that people aren’t generally keen on getting…
latest posts
